NEW YORK, Feb. 20, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Universal Health Services, Inc. (“Universal Health” or the “Company”) (NYSE:UHS) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Universal Health securities from February 26, 2015 through December 7, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/uhs.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Universal Health admitted patients based on its own financial considerations and not the patient’s medical needs; (2) Universal Health would keep patients admitted until their insurance payments ran out in order to bill for the maximum of its services; (3) accordingly, Universal Health’s revenues from inpatient care relied on unjustifiable practices; (4) due to the aforementioned, Universal Health lacked efficient internal control regarding its practices and policies of admitting patients; and (5) consequently, Universal Health’s public statements were materially false and misleading at all relevant times.
On December 7, 2016 BuzzFeed released its investigation into Universal Health “…based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents.” BuzzFeed reported that “[c]urrent and former employees from at least 10 UHS hospitals in nine states said they were under pressure to fill beds by almost any method – which sometimes meant exaggerating people’s symptoms or twisting their words to make them seem suicidal – and to hold them until their insurance payments ran out.” Following this news, Universal Health stock dropped $15.01 per share or nearly 12% to close at $111.36 on December 7, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/uhs or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Universal Health you have until February 21, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 



